Denali Therapeutics (DNLI) Total Debt (2022)
Denali Therapeutics (DNLI) posted quarterly Total Debt of $4.4 million for Q4 2022, up 204.09% quarter-over-quarter from $1.4 million in Q3 2022.
Powered by 
Analysis
Denali Therapeutics (DNLI) Total Debt (2022) Analysis & Trends
Denali Therapeutics (DNLI) has reported Total Debt for 1 consecutive years, with $4.4 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Total Debt changed N/A year-over-year to $4.4 million; the TTM figure through Dec 2022 stood at $4.4 million (changed N/A YoY), while the FY2022 annual figure was $4.4 million, changed N/A from the prior year.
- Total Debt grew to $4.4 million in Q4 2022 per DNLI's latest filing, from $1.4 million in the prior quarter.
- Across five years, Total Debt topped out at $4.4 million in Q4 2022 and bottomed at $1.4 million in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 1.07 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 9.34 Bn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Denali Therapeutics | 4.18 Bn | 4.18 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 4.39 Mn |
| Sep 30, 2022 | 1.44 Mn |
| Mar 31, 2022 | 2.71 Mn |